average weight loss with glp-1 agonists receptor for reduction in people living obesity but without diabetes: a living benefit–harm modelling study GLP-1 Agonists For Obesity In

Zepbound/Wegovy vs Mounjaro/Ozempic Mounjaro and Ozempic are the diabetes versions of Zepbound and Wegovy respectively

It facilitates and improves the use of both ingested nutritional calories and stored energy, accelerating fat-burning and controlling hunger

Additionally, exploring the efficacy of interclass drug switches could be a valuable area for future investigation to optimize weight management strategies for patients who experience challenges with one medication

This variability in outcomes likely stems from differences in study design, population characteristics, and follow-up duration

Real-world results vary based on dose, adherence, diet, activity level, and individual biology

Clinics such as Toniik highlight the benefits of combining medical approaches with evidence-based lifestyle changes to maximise results